Epizyme, Inc.
- Country
- ๐บ๐ธUnited States
- Ownership
- Public, Subsidiary
- Established
- 2007-01-01
- Employees
- 250
- Market Cap
- -
- Website
- http://www.epizyme.com
Tazemetostat Expanded Access Program for Adults With Solid Tumors
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT03874455
Epithelioid Sarcoma Natural History Study
- Conditions
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT03837678
- Locations
- ๐บ๐ธ
University of Colorado Cancer Center, Denver, Colorado, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
๐บ๐ธUniversity of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT03028103
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
๐บ๐ธUniversity of Arizona Cancer Center, Tucson, Arizona, United States
๐บ๐ธMoffitt Cancer Center, Tampa, Florida, United States
Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors
- First Posted Date
- 2017-01-05
- Last Posted Date
- 2024-03-22
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT03010982
- Locations
- ๐ฌ๐ง
The Clatterbridge Cancer Centre NHS Foundation Trust, Bebington, Wirral, United Kingdom
๐ฌ๐งRoyal Liverpool and Broadgreen University Hospital Trust, Liverpool, United Kingdom
A Study to Assess the Long-term Safety of Tazemetostat
- First Posted Date
- 2016-08-23
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT02875548
- Locations
- ๐บ๐ธ
California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
๐บ๐ธCentral Care Cancer Center, Bolivar, Missouri, United States
๐บ๐ธAstera Cancer Center, East Brunswick, New Jersey, United States
Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
- First Posted Date
- 2016-08-09
- Last Posted Date
- 2021-04-09
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 74
- Registration Number
- NCT02860286
- Locations
- ๐บ๐ธ
University of California, Los Angeles, Los Angeles, California, United States
๐บ๐ธCity of Hope National Medical Center, Los Angeles, California, United States
๐บ๐ธDana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
- Conditions
- Malignant Rhabdoid Tumors (MRT)Rhabdoid Tumors of the Kidney (RTK)Synovial SarcomaINI1-negative TumorsMalignant Rhabdoid Tumor of OvaryRenal Medullary CarcinomaEpithelioid SarcomaAtypical Teratoid Rhabdoid Tumors (ATRT)Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval)Any Solid Tumor With an EZH2 GOF Mutation
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 267
- Registration Number
- NCT02601950
- Locations
- ๐ซ๐ท
Institut Curie, Paris, France
๐ง๐ชUniversity Hospital Leuven, Leuven, Belgium
๐ซ๐ทCentre Leon Berard, Lyon, France
EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2015-11-11
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT02601937
- Locations
- ๐จ๐ฆ
The Hospital for Sick Children, Toronto, Ontario, Canada
๐บ๐ธDana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธTexas Children's Cancer and Hematology Center, Houston, Texas, United States
A Phase 1 Dose Escalation and Expanded Cohort Study of EPZ-5676 in the Treatment of Pediatric Patients With Relapsed/Refractory Leukemias Bearing a Rearrangement of the MLL Gene
- Conditions
- Interventions
- First Posted Date
- 2014-05-20
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT02141828
- Locations
- ๐บ๐ธ
Childrens Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธEmory Children's Healthcare of Atlanta, Atlanta, Georgia, United States
๐บ๐ธJohns Hopkins University, Baltimore, Maryland, United States
Study of Tazemetostat as Single Agent in Solid Tumors or B-cell Lymphomas and in Combination With Prednisolone in DLBCL
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Epizyme, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT01897571